H.C. Wainwright Thinks Checkpoint Therapeutics Inc’s Stock is Going to Recover


In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Checkpoint Therapeutics Inc (NASDAQ: CKPT), with a price target of $11. The company’s shares closed yesterday at $3.35, close to its 52-week low of $3.20.

According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -12.8% and a 34.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Checkpoint Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $11.

See today’s analyst top recommended stocks >>

Based on Checkpoint Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $5.92 million. In comparison, last year the company had a GAAP net loss of $4.38 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Checkpoint Therapeutics, Inc. is a biopharmaceutical company specializes in the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts